Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.41 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127088 | 0.89 | MRGPRX4 (0.49) | P2RX4LMNACYP19A1MRGPRX4PPIA | |
| SCHEMBL5099764 | 0.83 | MET (0.46) | P2RX4LMNACYP19A1MRGPRX4PPIA | |
| SCHEMBL7121896 | 0.81 | SGMS2 (0.46) | CYP19A1MRGPRX4PPIAPTGER1LRRK2 | |
| SCHEMBL7120699 | 0.81 | MET (0.38) | P2RX4CYP19A1RORCMETCYP2C9 | |
| SCHEMBL5089227 | 0.79 | RORC (0.45) | P2RX4LMNACYP19A1MRGPRX4ANO1 | |
| SCHEMBL7121876 | 0.79 | ALDH1A1 (0.49) | P2RX4LMNACYP19A1 | |
| SCHEMBL7117549 | 0.78 | SPHK1 (0.47) | P2RX4LMNACYP19A1MRGPRX4MET | |
| SCHEMBL6937058 | 0.78 | LMNA (0.39) | P2RX4LMNAMRGPRX4PPIARORC | |
| SCHEMBL7561577 | 0.77 | CYP19A1 (0.42) | P2RX4LMNACYP19A1MRGPRX4PPIA | |
| SCHEMBL7076172 | 0.77 | MEN1 (0.45) | P2RX4LMNACYP19A1MRGPRX4PPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | P2RX4 2133/4885LMNA 1147/4885CYP19A1 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.